Careium (CARE) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
5 Jun, 2025Executive summary
Achieved a positive Q4 and full-year 2024 with strong profitability, meeting the lower end of growth and upper end of profitability guidance.
Net sales grew 14.8% in Q4 2024 to SEK 228.9 million, with full-year growth of 5.6% to SEK 871 million, driven by both product and service sales.
Operating profit (EBIT) rose 59.3% in Q4 and 41.5% for the year, reflecting improved efficiency and higher sales.
Launched new products including the Abby mobile social alarm and i-Care Centre platform.
Renewed multi-year contract with Oslo municipality, increasing annual value from SEK 33 million to SEK 50 million.
Financial highlights
Q4 organic sales growth was 14.8% (12.5% adjusted for currency), with gross margin up to 44.4% from 40.2%.
Q4 EBITDA was SEK 43.8m (19.1% margin), EBIT SEK 26.5m (11.6% margin); full-year EBIT SEK 84m.
Free cash flow for Q4 was SEK 16.6m; full-year free cash flow was SEK 37m, down from SEK 62m, due to increased net working capital.
Cash at year-end was SEK 31.9m, with net debt reduced to SEK 164.9m (leverage 1.1).
Equity ratio increased to 64.6% (from 62.4%).
Outlook and guidance
Net sales, profitability, and free cash flow before acquisitions are expected to increase in 2025.
Softer first half of 2025 anticipated due to Swedish market delays, with stronger performance expected in the second half.
Focus on launching new hardware/software, expanding assisted living and direct-to-consumer, and evaluating acquisitions.
Latest events from Careium
- Q4 2025 delivered modest sales growth, lower EBIT, and stronger cash flow amid margin pressure.CARE
Q4 202516 Feb 2026 - Aging demographics fuel growth in care tech, with innovation and recurring revenue driving strategy.CARE
ABGSC Investor Days12 Jan 2026 - Q3 2025 delivered 6% sales growth, higher margins, and strong product sales despite one-off costs.CARE
Q3 202524 Oct 2025 - Sales fell but gross margin and cash flow improved; H2 growth expected from new contracts.CARE
Q2 202511 Jul 2025 - Sales dropped 7.2%, but strong margins and new platforms support growth targets.CARE
Q3 202413 Jun 2025 - Q2 sales and EBIT surged, driven by EU market gains despite UK/Nordic delays.CARE
Q2 202413 Jun 2025 - Gross margin rose to 44.5% despite lower sales, with growth outside Sweden and strong 2025 outlook.CARE
Q1 20255 Jun 2025